Active	Status	Sponsor type	Region	Phase	Filter
13 Active 14 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Heinemann, Volker
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients	Active, not recruiting	3	430	Europe	Ramucirumab, TAS 102	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH	Colorectal Cancer	12/23	06/24
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer	Recruiting	3	400	Europe, Canada, Japan, US, RoW	tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil	Seagen Inc., Merck Sharp & Dohme LLC	Colorectal Neoplasms	08/25	04/28
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma	Recruiting	3	200	Europe, US, RoW	Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice	TransThera Sciences (Nanjing), Inc.	Cholangiocarcinoma	05/26	08/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer	Recruiting	3	711	Europe, Canada, Japan, US, RoW	Dostarlimab, CAPEOX, FOLFOX	GlaxoSmithKline	Colonic Neoplasms, Neoplasms, Colon	12/28	12/30
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer	Completed	2	124	Europe	Aflibercept + mLV5FU2, mFOLFOX7	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi	Colorectal Cancer	02/24	02/24
NCT04034173: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation	Not yet recruiting	2	120	Europe	Panitumumab, Irinotecan, Folinic acid, 5-FU	Ludwig-Maximilians - University of Munich, Amgen, ClinAssess GmbH	Treatment Related Cancer	08/24	08/26
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer	Recruiting	2	150	Europe, Canada, Japan, US, RoW	Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A	GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd	Neoplasms, Rectal	11/26	10/29
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer	Completed	1/2	29	Europe, US	MEN1611, Cetuximab	Menarini Group, Menarini Ricerche S.p.A.	Metastatic Colorectal Cancer	01/24	02/24